Citing a decision based on safety, integrity, and trust connected to a product that “was not scientifically or ethically justifiable,” the US Department of Health and Human Services (HHS) notified Moderna on May 28 that it was terminating the company’s $776 million contract for the development of a bird flu vaccine for humans. That decision is undoubtedly the correct decision. Yet, meanwhile, realizing the danger to humans of the under-tested mRNA technology platform, the US government continues to fund research on H5 influenza mRNA-lipid nanoparticle (LNP) vaccines for use in cattle.
And to make matters worse—and essentially negate the progress made with the termination of HHS’s contract with Moderna—the US Food and Drug Administration (FDA) approved on May 31 a new Moderna COVID-19 mRNA jab called mNEXSPIKE®, which the DARPA partner noted was “for use in all adults 65 and older, as well as individuals 12 through 64 years of age with at least one underlying condition that put them at high risk for severe outcomes from COVID-19.”
While this article ponders the ongoing experimentation with mRNA technology in cattle for bird flu, the FDA’s approval of mNEXSPIKE® is reckless. Meanwhile, as we discuss cattle, the National Institutes of Health (NIH), the US Department of Agriculture (USDA), and the US Department of Energy continue to use federal funding to create mRNA-LNP jabs targeting highly pathogenic avian influenza (HPAI) H5N1 clade 2.3.4.4b in Holstein calves. The USDA allocated $824 million in emergency funding in May 2024 to bolster H5N1 efforts, including vaccine development for livestock, with ongoing research to evaluate effectiveness in lactating dairy cattle and eventually other animal species.
To help push the needle forward quickly, a 2025 preprint conducted by researchers at the USDA’s National Animal Disease Center and the University of Pennsylvania—who have received consulting fees from Big Pharma groups, including Pfizer—aims to paint the research in a glowing light, noting that an H5 mRNA-LNP vaccine induced robust antibody and T-cell responses in calves, offering partial protection against H5N1. However, notably, the preprint failed to report biodistribution data, only mentioning intramuscular administration but not whether the mRNA or LNPs were tracked in tissues beyond the intramuscular injection site. But make no mistake. We know that both the mRNA and toxic LNPs can also enter the bloodstream, leading to systemic distribution to organs across the body, including the liver, spleen, heart, and other tissues.
Concerningly, we also know mRNA-LNPs cross the blood-brain barrier, settling into essentially every organ in the human body, causing damage to the brain, heart, liver, and bone marrow in humans. Why isn’t this deadly hazard being studied in cattle? Thus far, no studies have directly quantified H5 mRNA-LNP biodistribution in cattle, particularly in lactating dairy cows, where H5N1 replication in the mammary glands raises significant concerns about milk safety.
Hellbound and Down 